longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

MBX Biosciences

MBX

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -28.43, below the reasonable range, cheaper than 80.84% of the time in the past 1 years, and the industry ranks 211/257, the industry Median -1.27.

-28.43xP/E
$61.57Stock price
$-2.17Earnings per share
-28.43xP/E
Stock price$61.57Earnings per share$-2.17

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-17.63x
Typical range
-28.12x–-14.71x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company
-56.40x14.24%$58.89B
BAYZFUSBayer Aktiengesellschaft
-27.45x--$55.39B
BAYRYUSBayer
-27.37x--$55.21B
VTRSUSViatris
-47.60x110.35%$19.55B
VREOFUSVIREO GROWTH INC
-171.39x--$11.50B
ELANUSElanco Animal Health
-57.39x129.36%$11.42B
AXSMUSAxsome Therap
-57.94x27.32%$11.10B
CURLFUSCuraleaf Holdings, Inc.
-146.83x--$7.64B
BLTEUSBelite Bio
-66.57x29.87%$6.81B
DFTXUSDefinium Therapeutics
-14.38x53.32%$5.09B
EWTXUSEdgewise Therapeutics
-25.02x137.29%$4.93B
MANEUSVeraDermics
-41.03x97.39%$4.28B
AMLXUSAmylyx Pharmaceuticals
-26.93x1.76%$4.10B
ELVNUSEnliven Therapeutics
-33.98x1.17%$3.60B
TARSUSTarsus Pharmaceuticals
-73.31x34.09%$3.41B
MBXUSMBX Biosciences
-28.43x30.54%$2.97B
RGCUSRegencell Bioscience
-399.27x--$2.81B
PHVSUSPharvaris BV
-13.29x7.70%$2.64B
GPCRUSStructure Therapeutics
-11.78x104.48%$2.53B
SUPNUSSupernus Pharma
-21.89x70.59%$2.41B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.